NEA Management Company LLC's Q1 2024 13F: 3 new positions, 3 exits
Form 13F-HR for the quarter ended Mar 31, 2024 · filed May 15, 2024 · 44 reported positions · accession 0001012975-24-000231
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Reduced | GERON CORP (GERN) | 3.2% | 2.6% | −0.6 pts | −10M sh | −44% |
| New | ORIC PHARMACEUTICALS INC (ORIC) | — | 1.3% | +1.3 pts | +1.5M sh | new |
| Increased | REGULUS THERAPEUTICS INC (RGLS) | 0.2% | 1.2% | +1.0 pts | +4.52M sh | +232% |
| Reduced | SAGIMET BIOSCIENCES INC (SGMT) | 1.3% | 0.7% | −0.6 pts | −1.85M sh | −48% |
| Reduced | MYND AI INC (MYND) | 0.1% | 0.1% | 0.0 pts | −20M sh | −85% |
| Exited | AFFIMED NV (AFMD) | 0.2% | — | −0.2 pts | −4.43M sh | −100% |
| Reduced | GLYCOMIMETICS INC (GLYC) | 0.7% | 0.7% | 0.0 pts | −929K sh | −20% |
| New | AFFIMED NV (AFMDQ) | — | 0.1% | +0.1 pts | +443K sh | new |
| Exited | ACRIVON THERAPEUTICS INC (ACRV) | 0.1% | — | −0.1 pts | −430K sh | −100% |
| New | XERIS BIOPHARMA HOLDINGS INC (XERS) | — | 0.1% | +0.1 pts | +419K sh | new |
| Exited | ADDEX THERAPEUTICS LTD (ADXN) | 0.0% | — | 0.0 pts | −9,000 sh | −100% |
| Reduced | SYNLOGIC INC (SYBX) | 0.7% | 0.3% | −0.4 pts | −2 sh | 0% |
| Reduced | WHEELS UP EXPERIENCE INC (UP) | 0.0% | 0.0% | 0.0 pts | −1 sh | 0% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 70.4% of the equity book
Changes in the top 10 this quarter: NN entered · GERN left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | ARCELLX INC (ACLX) | 13.9% | 16.2% | |
| 2 | CRISPR THERAPEUTICS AG (CRSP) | 6.6% | 11.2% | |
| 3 | RHYTHM PHARMACEUTICALS INC (RYTM) | 8.9% | 7.8% | |
| 4 | SAVARA INC (SVRA) | 7.7% | 7.6% | |
| 5 | COURSERA INC (COUR) | 16.6% | 6.7% | |
| 6 | KORRO BIO INC (KRRO) | 2.7% | 6.0% | |
| 7 | VERONA PHARMA PLC (VRNA) | 7.4% | 5.6% | |
| 8 | MONTE ROSA THERAPEUTICS INC (GLUE) | 2.9% | 3.4% | |
| 9 | NEXTNAV INC (NN) | 2.4% | 3.3% | Entered the top 10 |
| 10 | CVRX INC (CVRX) | 5.0% | 2.7% | |
| — | GERON CORP (GERN) | 3.2% | 2.6% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).